Dabigatran, Product Familiarisation Programmes, who benefits, who shouldn't get it? [PDF]
, 2012 Helen Curley, Charles Denaro
openalex +1 more source
Rebound warfarin toxicity presenting with spontaneous hemopericardium in cardiac tamponade: a case report. [PDF]
Int J Emerg MedRinzin U, Gurung M.
europepmc +1 more source
Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable? [PDF]
, 2012 Francisco Marı́n +2 more
openalex +1 more source
Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System. [PDF]
J Clin MedSridharan K, Sivaramakrishnan G.
europepmc +1 more source
Analysis of Upper Gastrointestinal Adverse Events Associated with Oral Anticoagulants and Potential Drug Interactions with Cardiovascular Drugs: Exploratory Study Using FDA Adverse Event Reporting System. [PDF]
Pharmaceuticals (Basel)Cheon S, Park J, Oh D, Kim YS, Chung JE.
europepmc +1 more source
Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA): Table 1 [PDF]
, 2013 L. van Veen +4 more
openalex +1 more source
Trends and Hot Spots in Research Related to Rivaroxaban: Bibliometric Analysis. [PDF]
Clin PractPawlak K +3 more
europepmc +1 more source
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Circulation, 2014 S. Schulman +10 more
semanticscholar +1 more source
Adherence to anticoagulant treatment with dabigatran in a real-world setting [PDF]
, 2013 Sam Schulman +3 more
openalex +1 more source
Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric bypass surgery [PDF]
, 2013 Daniel Lee +3 more
openalex +1 more source